158 related articles for article (PubMed ID: 35049226)
21. MicroRNAs in body fluids as biomarkers for non-small cell lung cancer: a systematic review.
Huang Y; Hu Q; Deng Z; Hang Y; Wang J; Wang K
Technol Cancer Res Treat; 2014 Jun; 13(3):277-87. PubMed ID: 24066954
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies.
Wu R; Jiang Y; Wu Q; Li Q; Cheng D; Xu L; Zhang C; Zhang M; Ye L
Tumour Biol; 2014 Sep; 35(9):8829-36. PubMed ID: 24880588
[TBL] [Abstract][Full Text] [Related]
23. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
[TBL] [Abstract][Full Text] [Related]
24. Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Liu J; Han Y; Liu X; Wei S
Technol Cancer Res Treat; 2020; 19():1533033820973276. PubMed ID: 33251978
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic value of serum miR-21 in patients with ovarian cancer: a systematic review and meta-analysis.
Qiu L; Weng G
J Ovarian Res; 2022 May; 15(1):51. PubMed ID: 35501921
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-223 in gastrointestinal cancers: A systematic review and diagnostic meta-analysis.
Aalami AH; Abdeahad H; Mesgari M; Sahebkar A
Eur J Clin Invest; 2021 Feb; 51(2):e13448. PubMed ID: 33244751
[TBL] [Abstract][Full Text] [Related]
28. A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.
Wang C; Ding M; Xia M; Chen S; Van Le A; Soto-Gil R; Shen Y; Wang N; Wang J; Gu W; Wang X; Zhang Y; Zen K; Chen X; Zhang C; Zhang CY
EBioMedicine; 2015 Oct; 2(10):1377-85. PubMed ID: 26629532
[TBL] [Abstract][Full Text] [Related]
29. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
30. The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis.
Yang H; Wang H; Zhang C; Tong Z
Oncotarget; 2016 Sep; 7(39):63283-63293. PubMed ID: 27557519
[TBL] [Abstract][Full Text] [Related]
31. The Diagnostic Value of Circulating miR-29 Family for Digestive System Malignancies: A Meta-Analysis.
Zou S; Chen F; Zhang L; Liu C; Chen H
Lab Med; 2024 Jan; 55(1):1-7. PubMed ID: 37172311
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
33. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
34. The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies.
Wang N; Zhang X; Wang F; Zhang M; Sun B; Yin W; Deng S; Wan Y; Lu W
SLAS Technol; 2021 Feb; 26(1):42-54. PubMed ID: 32659150
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR.
He RQ; Cen WL; Cen JM; Cen WN; Li JY; Li MW; Gan TQ; Hu XH; Chen G
Cell Physiol Biochem; 2018; 46(3):925-952. PubMed ID: 29669324
[TBL] [Abstract][Full Text] [Related]
36. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis.
Fu L; Wang R; Yin L; Shang X; Zhang R; Zhang P
Int J Biol Markers; 2019 Sep; 34(3):251-261. PubMed ID: 31436122
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
38. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
39. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer.
Jiang LP; Zhu ZT; He CY
Future Oncol; 2016 May; 12(9):1105-15. PubMed ID: 27033050
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Luo J; Shen L; Zheng D
Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
